Partners & Projects

Wellcome Trust

ServareGMP’s anti-cholera program is primarily funded by the Wellcome Trust, a partnership for which we are deeply grateful.

The UK headquartered Wellcome Trust is one of the leading global charitable foundations. It is politically and financially independent, funded by a £38.2 billion investment portfolio. With a deep and lengthy commitment to global health equity and a mission to improve same through broad based research.

Wellcome’s strategy includes grant funding, advocacy campaigns and partnerships to find solutions for today’s urgent health challenges.

Wellcome works to improve health for everyone by funding research, leading policy and advocacy campaigns, and building global partnerships.

Wellcome works with people and organizations using science to solve health challenges. We fund discovery research into life, health and wellbeing, and we support research to find solutions to three health challenges: mental health, infectious disease and climate.

Wadsworth Center, Department of Health, State of New York

The Wadsworth Center, located in Albany, New York. The Wadsworth Center is the research-intensive public health laboratory of the New York State Department of Health.

The Wadsworth Center has over 100 principal investigators and more than 1,000 staff in four locations. Scientists at the Wadsworth Center study public health issues, such as drug resistance to emerging infections, environmental exposures, and basic biological processes that contribute to human health and disease. Additionally, as the state's public health reference laboratory, the Wadsworth Center is responsible for responding to public health threats, developing methods to detect microbes and genetic disorders, measuring and analyzing environmental chemicals, and licensing clinical and environmental laboratories.

Mapp Biopharmaceutical

Mapp Biopharmaceutical is an American biopharmaceutical company founded in 2003 by Dr. Larry Zeitlin and Dr. Kevin Whaley. Mapp Biopharmaceutical is based in San Diego, California. Mapp is responsible for the research and development of the anti-Ebola multiple mAb cocktail ZMapp.

Under the guidance of Drs Whaley and Zeitlin, Mapp Biopharmaceutical works to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. Other Mapp programs include HIV/HSV, Marburg, Nipah/Hendra, Crimean Congo Hemorrhagic Fever, Hantavirus, RSV, Anti-toxins and Anti-bacterials.


ATUM is an American biotechnology company located in California, which provides tools for the life sciences, from design and synthesis of optimized DNA to protein production and GMP cell line development. ATUM’S technology platform combines DoE with machine learning tools to optimize biological systems for the properties crucial for success. ATUM’s technology provides an integrated bioengineering suite of solutions for the design and manufacture of optimized genes, vectors, enzymes, antibodies and cell lines. ATUM is committed to fostering equity in health and medicines.

Thanks to the efforts of CEO Dr. Jeremy Minshull, Ph.D., Chief Executive Officer; Dr. Oren Beske, Ph.D. Strategic Programs, ATUM is has donated a high-performance commercial cell line and GMP Master Cell Bank to foster ServareGMP’s efforts to meet the needs of vulnerable populations.